Evidence map›Paper›PMID 39470194›Full record

ArticleAntimicrobial agents and chemotherapy2024

A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens.

Nora M R Molasky, Zhongsheng Zhang, J Robert Gillespie, John Domagala, Dawn Reyna, Elke Lipka, Erkang Fan, Frederick S Buckner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Microbiology spectrum · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nora M R MolaskyCenter for Emerging and Re-emerging Infectious Diseases, Department of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.
Zhongsheng ZhangDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
J Robert GillespieCenter for Emerging and Re-emerging Infectious Diseases, Department of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.
John DomagalaTherapeutic Systems Research Laboratories, Inc., Ann Arbor, Michigan, USA.
Dawn ReynaTherapeutic Systems Research Laboratories, Inc., Ann Arbor, Michigan, USA.
Elke LipkaTherapeutic Systems Research Laboratories, Inc., Ann Arbor, Michigan, USA.
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.ORCID 0009-0009-8840-1581
Frederick S BucknerCenter for Emerging and Re-emerging Infectious Diseases, Department of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-7796-6477

Funding

Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.R44AI134190 · NIAID · TSRL, INC. · PI LIPKA, ELKE · 2017 to 2025
$6.0M
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas diseaseR01AI152358 · NIAID · UNIVERSITY OF WASHINGTON · PI BUCKNER, FREDERICK SIMMONS, FAN, ERKANG · 2020 to 2023
$3.1M
NIAID NIH HHS R01 AI152358NIAID NIH HHS R44 AI134190
6 · The paper itself

Abstract

New antibiotics are needed to treat gram-positive bacterial pathogens.

Indexed as

Anti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusMethionine-tRNA LigaseMicrobial Sensitivity TestsStreptococcus pyogenesAnimalsEnterococcusEnzyme InhibitorsFemaleGram-Positive BacteriaGram-Positive Bacterial InfectionsLinezolidMiceStaphylococcus aureusAnti-Bacterial AgentsEnzyme InhibitorsLinezolidMethionine-tRNA Ligaseantibioticsdrug discoveryStaphylococcustRNA synthesis

Identifiers

PMID39470194
PMCPMC11619354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.